http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022289761-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bbd633ef7f9bfa58d0405f4f534e3c3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 |
| filingDate | 2022-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cdc5f8e24f34cc58b62773c622e261d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3a829bd7ec47353dd9b948940f741ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5bf06864d783f40b33da94a9a098b46 |
| publicationDate | 2022-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022289761-A1 |
| titleOfInvention | Crystalline form b of tetrahydrothienopyridine compound, preparation method, composition and application thereof |
| abstract | Disclosed in the present invention are a crystalline form B of a tetrahydrothienopyridine compound having a structure as represented by Compound I, a preparation method, a composition and an application thereof, for use in solving the problems in the prior art of lots of impurities, low content, bad crystalline form stability, and inability to form a drug. The crystalline form B uses Cu-Kα radiation, and X-ray powder diffraction expressed at a 2θ angle has characteristic peaks at 11.21±0.2°, 12.61±0.2°, 14.69±0.2°, 16.14±0.2°, 17.81±0.2°, 20.22±0.2°, and 22.10±0.2°. The crystalline form B of the present invention has few of impurities, good stability, good crystallinity, and reproducibility, and is suitable for industrial production. Moreover, the crystalline form B has an unexpectedly stronger anti-ADP-induced platelet aggregation effect and better fluidity. |
| priorityDate | 2019-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.